rinvoq for psoriasis
Psoriasis treatments
rinvoq for psoriasis
Psoriasis treatments

Rinvoq

Rinvoq (upadacitinib) is an oral medication used to treat moderate to severe plaque psoriasis by targeting specific immune pathways that drive inflammation and plaque formation.
Rinvoq is an oral Janus kinase (JAK) inhibitor that reduces inflammation and helps manage moderate to severe plaque psoriasis.
It is ideal for individuals with moderate to severe psoriasis who have not responded to other systemic treatments or biologics.
Improvements are typically seen within 2–4 weeks of starting treatment.
This treatment is prescribed for adults with moderate to severe psoriasis who have not responded adequately to topical therapies or other systemic treatments. Rinvoq is taken once daily as an oral tablet. See pricing details here.

Real patients, real results

How effective is Rinvoq

Clinically proven results

Significant skin clearance and reduced inflammation with consistent daily treatment.*
Clinical studies show that Rinvoq helps reduce psoriasis severity and improve skin clarity by controlling overactive immune responses.
*Improvement may be seen as early as 4–8 weeks, with continued benefits over time.
Rinvoq should be used only under medical supervision. For more information, see Important Safety Information.

How DermOnDemand Works

Common Question

Common side effects include headache, nausea, and upper respiratory infections. Rarely, it may increase the risk of blood clots or serious infections.
Yes, blood tests may be needed to monitor for potential side effects like liver function changes or anemia.